Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorSan Raffaele Telematic University
About this trial
This observational retrospective study aims to evaluate changes in taste perception, eating habits, and behavioral aspects in adults treated with GLP-1 receptor agonists for weight loss. Participants include adults aged 18-60 receiving treatment at specialized nutrition centers in Italy. Data are collected from clinical records, dietary questionnaires, and metabolic assessments before and after at least 12 weeks of GLP-1 agonist treatment. The study's primary goal is to understand how these treatments affect food preferences and taste perception. Secondary outcomes include changes in body weight, body composition, gastrointestinal side effects, and treatment adherence. All data are anonymized and collected according to ethical guidelines.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Adults with obesity receiving GLP-1 agonist treatment at specialized nutrition centers in Italy, assessed retrospectively.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
150 Participants
are grouped into 1 trial groupGroup A: GLP-1 Agonist Treated Patients
Trial outcomes
Primary outcomes
1
Change in taste perception and food preferences
Assessment of patients' taste perception changes and shifts in eating habits using validated questionnaires and behavioral surveys.
Time frame
From baseline to 12 weeks after GLP-1 agonist treatmentSecondary outcomes
1
Change in body weight
Measured in kilograms to assess weight loss effectiveness.
Time frame
From baseline to 12 weeks after treatment2
Gastrointestinal side effects
Recording of nausea, vomiting, diarrhea, or other GI symptoms via patient reports.
Time frame
Throughout the treatment period3
Treatment adherence
Assessment of continued use and discontinuation reasons of GLP-1 agonists.
Time frame
Throughout the study durationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov